Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2461 - Cell-free circulating DNA as Independent Prognostic Markers in Metastatic Breast Cancer

Date

11 Sep 2017

Session

Poster display session

Presenters

Jie Cheng

Citation

Annals of Oncology (2017) 28 (suppl_5): v74-v108. 10.1093/annonc/mdx365

Authors

J. Cheng1, H. Surowy1, M. Wallwiener2, T. Holland-Letz3, K. Cuk1, S. Schott2, A. Trumpp4, K. Pantel5, C. Sohn2, A. Schneeweiss6, B. Burwinkel1

Author affiliations

  • 1 Division Of Molecular Epidemiology, German Cancer Research Center, 69120 - Heidelberg/DE
  • 2 Department Of Gynecology And Obstetrics, Women's Hospital, University of Heidelberg, 69120 - Heidelberg/DE
  • 3 Department Of Biostatistics, German Cancer Research Center, 69120 - Heidelberg/DE
  • 4 Division Of Stem Cells And Cancer, German Cancer Research Center, 69120 - Heidelberg/DE
  • 5 University Hospital Hamburg-eppendorf, Department of Tumor Biology, 20251 - Hamburg/DE
  • 6 Division Gynecologic Oncology, National Center for Tumor Diseases (NTC) University Hospital, 69120 - Heidelberg/DE
More

Resources

Abstract 2461

Background

Blood-based biomarkers like microRNAs, cell-free DNA and circulating tumor cells hold great promise as they are reproducible and easily accessible in cancer patients. Cell-free DNA variables, such as cell-free DNA concentrations (cfDNA conc) and cell-free DNA integrity (cfDI), have great potential as diagnostic and prognostic markers in breast cancer patients. Here we investigated the potential prognostic ability of cfDNA conc and cfDI in a prospective study cohort of metastatic breast cancer (MBC) patients.

Methods

Blood was collected for cfDNA extraction from patients when enrolled about to start the first cycle of systematic therapy at baseline (MBCBL) and after the first cycle of systematic therapy (MBC1C). cfDNA conc and cfDI in blood plasma were evaluated by measuring the short and long fragments of two repetitive DNA elements, ALU (ALU-111bp, ALU-260bp) and LINE1 (LINE1-97bp, LINE1-266bp), by quantitative PCR. In total, 268 patients were included in this study. cfDNA conc and cfDI was compared between these two groups. The prognostic ability of cfDNA variables was evaluated by univariate and multivariate Cox regression model.

Results

A significant increase of cfDI (P = 1.21E-7 for ALU and P = 1.87E-3 for LINE1) and decrease of cfDNA conc (P = 1.17E-3 for ALU and P = 1.60E-2 for LINE1) were observed between patients at MBCBL and patients at MBC1C. Multiple Cox regression model indicated that cfDI and cfDNA conc can be used as independent prognostic markers in patients after one cycle of therapy with odds ratio (OR) and 95% confidence interval (CI) of 0.70 (0.48 - 1.01) for ALU cfDI, 0.63 (0.44 - 0.92) for LINE1 cfDI, 2.44 (1.68 - 3.53) for ALU cfDNA conc, 2.12 (1.47 - 3.06) for LINE1 cfDNA conc for overall survival. When four cfDNA variables were combined, it can reach an OR of 2.53 (1.77-3.62) for overall survival analysis of patients.

Conclusions

In summary, our results showed a decreased cfDNA conc and increased cfDI from the enrollment of the study to the first cycle of systematic therapy in MBC patients. cfDNA conc and cfDI can serve as independent prognostic markers in MBC patients after the first cycle of systematic therapy.

Clinical trial identification

Legal entity responsible for the study

Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University of Heidelberg, Heidelberg, Germany

Funding

The University Hospital of Heidelberg, Heidelberg, Germany; the German Cancer Research Center (DKFZ), Heidelberg, Germany

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.